<?xml version="1.0" encoding="UTF-8"?>
<p id="Par39">Performing SSM as a back-up test in addition to Xpert (thereby allowing same-day diagnosis for all smear-positive patients) improved the epidemiological impact and cost-effectiveness of centralized testing. For example, assuming moderate decentralized testing volume and no cost-sharing for specimen transport, the probability that decentralized testing would be cost-effective relative to centralized testing was estimated as 0.61 
 <bold>
  <italic>(compared to 0.98 at baseline). For complete one-way sensitivity analyses results, please see Additional file</italic>
 </bold>
 <xref rid="MOESM1" ref-type="media">1</xref>
 <bold>
  <italic>, Section S3.3</italic>
 </bold>.
</p>
